|
|
Volumn 4, Issue 7, 2007, Pages 381-
|
|
The Provenge® decision
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BCG VACCINE;
PROVENGE;
CANCER VACCINE;
SIPULEUCEL T;
SIPULEUCEL-T;
TISSUE EXTRACT;
UNCLASSIFIED DRUG;
CANCER IMMUNIZATION;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG TREATMENT FAILURE;
EDITORIAL;
EVIDENCE BASED MEDICINE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
IMMUNOSTIMULATION;
IMMUNOTHERAPY;
OUTCOME ASSESSMENT;
PATIENT ATTITUDE;
PRIORITY JOURNAL;
PROSTATE CANCER;
ADVISORY COMMITTEE;
CLINICAL TRIAL;
LEGAL ASPECT;
MALE;
PROSTATE TUMOR;
STANDARD;
UNITED STATES;
ADVISORY COMMITTEES;
CANCER VACCINES;
CLINICAL TRIALS;
DRUG APPROVAL;
HUMANS;
MALE;
PROSTATIC NEOPLASMS;
TISSUE EXTRACTS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 34447253820
PISSN: 17434254
EISSN: 17434262
Source Type: Journal
DOI: 10.1038/ncponc0854 Document Type: Editorial |
|
Times cited : (7)
|
|
References (0)
|
